Pernix Therapeutics Holdings Inc. (PTX): Billionaire Steve Cohen’s Point72 Asset Management Ups Its Stake

Page 6 of 9 – SEC Filing
Item 1(a)
Name of Issuer:
Pernix Therapeutics Holdings, Inc.
Item 1(b)
Address of Issuer’s Principal Executive Offices:
10 North Park Place, Suite 201, Morristown, New Jersey 07960
Item 2(a)
Name of Person Filing:
This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of Common Stock, $0.01 par value per share (“Shares”), of the Issuer held by certain investment funds it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by certain investment funds managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with respect to Shares held by certain investment funds it manages; and (iv) Steven A. Cohen with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.
Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies and Steven A. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.
Item 2(b)
Address or Principal Business Office:
The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 330 Madison Avenue, New York, NY 10173.
Item 2(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership.  Point72 Capital Advisors Inc. is a Delaware corporation.  Cubist Systematic Strategies is a Delaware limited liability company.  Mr. Cohen is a United States citizen.
Item 2(d)
Title of Class of Securities:
Common Stock, par value $0.01 per share
Item 2(e)
CUSIP Number:
71426V108
Item 3
Not Applicable

Follow Pernix Therapeutics Holdings Inc. (NASDAQ:PTX)